Anti-HBV effect of TAT-HBV targeted ribonuclease

World Journal of Gastroenterology

Volumn 9, Issue 7, 2003, Pages 1525-1528

  Ding, Jin ^a   Liu, Jun ^a   Xue, Cai Fang ^a   Gong, Wei Dong ^a   Li, Ying Hui ^a   Zhao, Ya ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HEPATITIS B(E) ANTIGEN; HYALURONIC ACID; RIBONUCLEASE; TRANSACTIVATOR EOSINOPHIL PROTEIN X; TRANSACTIVATOR HEPATITIS B VIRUS CORE PROTEIN; TRANSACTIVATOR HEPATITIS B VIRUS TARGETED RIBONUCLEASE FUSION PROTEIN; TRANSACTIVATOR HEPATITIS B VIRUS TARGETED RIBONUCLEASE FUSION PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BACTERIUM TRANSFORMATION; CELL GROWTH; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG PURIFICATION; DRUG SYNTHESIS; ESCHERICHIA COLI; EXPRESSION VECTOR; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LIVER CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 0043066632     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i7.1525     Document Type: Article

References (45)

1. Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 2001; 24: 247-256
2. Schwarze SR, Dowdy SF. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000; 21: 45-48
3. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: Unrestricted delivery into all cells? Trends Cell Biol 2000; 10: 290-295
4. Vives E, Brodin P, Lebieu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-16017
5. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994; 91: 664-668
6. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-1572
7. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27kip1 induces cell migration. Natl Med 1998; 4: 1449-1452
8. Chellaiah MA, Soga N, Swanson S, McAllister S, Alvarez U, Wang D, Dowdy SF, Hruska KA. Rho-A is critical for osteoclast podosome organization, motility and bone resorption. Biol Chem 2000; 275: 11993-12002
9. Shi H, Wang FS. Host factors in chronicity of hepatitis B virus infection and their significance in clinic. Shijie Huaren Xiaohua Zaizhi 2001; 9: 66-69
10. Befeler AS, Di Bisceglie AM. Hepatitis B. Infect Dis Clin North Am 2000; 14: 617-632
11. Maddrey WC. Hepatitis B: An important public health issue. J Med Virol 2000; 61: 362-366
12. Lau GK. Hepatitis B infection in China. Clin Liver Dis 2001; 5: 361-379
13. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356-1361
14. Guo SP, Wang WL, Zhai YQ, Zhao YL. Expression of nuclear factor-kappa B in hepatocellular carcinoma and its relation with the X protein of hepatitis B virus. World J Gastroenterol 2001; 7: 340-344
15. Shi DR, Lu L, Wang JH, Dong CL, Cong WT. HBV DNA distribution of hepatitis B virus in pancreas and liver of patients with cirrhosis. Shijie Huaren Xiaohua Zazhi 2000; 8: 751-754
16. Wu C, Cheng ML, Ding YS, Liu RC, Li J, Wang WL, Hu L. A five-year follow up survey of risk factor of viral hepatic cirrhosis. Shijie Huaren Xiaohua Zazhi 2000; 8: 1365-1367
17. Wang HY, Yan RQ, Long JB, Wu QL. Cyclin D1 amplification is associated with HBV DNA integration and pathology in human hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 1999; 7: 98-100
18. Fan ZR, Yang DH, Qin HR, Huang CC, Xu C, Qiu QL. Expression of IGF-I, IGF-I receptor mRNA in hepatocellular carcinomas and adjacent nontumor tissue. Shijie Huaren Xiaohua Zazhi 1999; 7: 848-850
19. Yan JC, Ma Y, Chen WB, Shun XH. Pathological significance of expression of intrahepatic smooth muscle fiber in hepatitis B. Shijie Huaren Xiaohua Zazhi 2000; 8: 1242-1246
20. Zhai SH, Liu JB, Liu YM, Zhang LL, Du ZH. Expression of HBsAg, HCV-Ag and AFP in liver cirrhosis and hepatocarcinoma. Shijie Huaren Xiaohua Zazhi 2000; 8: 524-527
21. Feitelson MA. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol 1999; 181: 188-202
22. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001; 82: 77-100
23. Zhuang L, You J, Tang BZ, Ding SY, Yan KH, Peng D, Zhang YM, Zhang L. Preliminary results of Thymosin-a1 versus interferon-á-treatment in patient with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2001; 7: 407-410
24. Xie Q, Guo Q, Zhou XQ, Gu RY. Effect of adenine arabinoside monophosphate coupled to lactosaminated human serum albumin on duck hepatitis B virus. Shijie Huaren Xiaohua Zazhi 1999; 7: 125-126
25. Li J, Tang B. Effect on replication of hepatitis B virus by Chinese traditional medicine. Shijie Huaren Xiaohua Zazhi 2000; 8: 945-946
26. Zhu Y, Wang YL, Shi L. Clinical analysis of the efficacy of interferon alpha treatment of hepatitis. World J Gastroenterol 1998; 4:85-86
27. Xu KC, Wei BH, Yao XX, Zhang WD. Recently therapy for chronic hepatitis B virus by combined traditional Chinese and Western medicine. Shijie Huaren Xiaohua Zaizhi 1999; 7: 970-974
28. Lau GK. Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000; 15(Suppl): E46-52
29. Guan R. Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol 2000; 15 (Suppl): E34-40
30. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118 (Suppl): S83-103
31. Schiff ER. Lamivudine for hepatitis B in clinical practice. J Med Virol 2000; 61: 386-391
32. Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999; 58: 101-141
33. Malik AH, Lee WM. Chronic hepatitis B virus infection: Treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723-731
34. Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs 2000; 60: 701-710
35. Song YH, Lin JS, Liu NZ, Kong XJ, Xie N, Wang NX, Jin YX, Liang KH. Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro. World J Gastroenterol 2002; 8: 91-94
36. Li YH, Liu J, Xue CF. Construction of HBV targeted ribonuclease and its expression in 2.2.15 cell line. Xibao Yu Fenzi Mianyixue Zazhi 2002; 18: 217-220
37. Liu J, Li YH, Xue CF, Ding J, Gong WD, Zhao Y. HBV targeted ribonuclease can inhibit HBV replication. World J Gastroenterol 2003; 9: 295-299
38. Ding J, Liu J, Xue CF, Li YH, Gong WD. Construction and expression of prokaryotic expression vector for pTAT-HBV targeted ribonuclease fusion protein. Xibao Yu Fenzi Mianyixue Zazhi 2003; 19: 49-51
39. Green M, Loewenstein PM. Automomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988; 55: 1179-1188
40. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193
41. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-10450
42. Elloit G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-233
43. Chellaiah MA, Soga N, Swanson S, McAllister S, Alvarez U, Wang D, Dowdy SF, Hruska KA. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem 2000; 275: 11993-2002
44. Schutze-Redelmeier MP, Gournier H, Garcia-Pons F, Moussa M, Joliot AH, Volovitch M, Prochiantz A, Lemonnier FA. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J Immunol 1996; 157: 650-655
45. Gottesman S, Wickner S, Maurizi MR. Protein quality control: Triage by chaperones and proteases. Genes Dev 1997; 11: 815-823